Switch theme
Sign up to access all valuation multiples
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.
2003
108
LTM Revenue -$0.4M
LTM EBITDA -$63.0M
$154M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Nanobiotix has a last 12-month revenue of -$0.4M and a last 12-month EBITDA of -$63.0M.
In the most recent fiscal year, Nanobiotix achieved revenue of -$12.5M and an EBITDA of -$62.6M.
Nanobiotix expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Nanobiotix valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $32.3M | -$12.5M | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$32.3M | -$62.6M | XXX | XXX | XXX |
| EBITDA Margin | -100% | 502% | XXX | XXX | XXX |
| Net Profit | -$61.3M | -$42.6M | XXX | XXX | XXX |
| Net Margin | -190% | 342% | XXX | XXX | XXX |
| Net Debt | $6.7M | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Nanobiotix's stock price is EUR 3 (or $3).
Nanobiotix has current market cap of EUR 142M (or $153M), and EV of EUR 143M (or $154M).
See Nanobiotix trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $154M | $153M | XXX | XXX | XXX | XXX | $-1.31 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Nanobiotix has market cap of $153M and EV of $154M.
Nanobiotix's trades at -418.3x LTM EV/Revenue multiple, and -2.4x LTM EBITDA.
Analysts estimate Nanobiotix's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Nanobiotix and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $154M | XXX | XXX | XXX |
| EV/Revenue | -12.4x | XXX | XXX | XXX |
| EV/EBITDA | -2.5x | XXX | XXX | XXX |
| P/E | -2.1x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -7.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpNanobiotix's NTM/LTM revenue growth is -9279%
Nanobiotix's revenue per employee for the last fiscal year averaged -$0.1M, while opex per employee averaged $0.6M for the same period.
Over next 12 months, Nanobiotix's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Nanobiotix's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Nanobiotix and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -139% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 502% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 94% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -8776% | XXX | XXX | XXX | XXX |
| Revenue per Employee | -$0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.6M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | -173% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | -349% | XXX | XXX | XXX | XXX |
| Opex to Revenue | -489% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Nanobiotix acquired XXX companies to date.
Last acquisition by Nanobiotix was XXXXXXXX, XXXXX XXXXX XXXXXX . Nanobiotix acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Nanobiotix founded? | Nanobiotix was founded in 2003. |
| Where is Nanobiotix headquartered? | Nanobiotix is headquartered in France. |
| How many employees does Nanobiotix have? | As of today, Nanobiotix has 108 employees. |
| Who is the CEO of Nanobiotix? | Nanobiotix's CEO is Dr. Laurent Levy, PhD. |
| Is Nanobiotix publicy listed? | Yes, Nanobiotix is a public company listed on PAR. |
| What is the stock symbol of Nanobiotix? | Nanobiotix trades under NANO ticker. |
| When did Nanobiotix go public? | Nanobiotix went public in 2012. |
| Who are competitors of Nanobiotix? | Similar companies to Nanobiotix include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Nanobiotix? | Nanobiotix's current market cap is $153M |
| What is the current revenue of Nanobiotix? | Nanobiotix's last 12-month revenue is -$0.4M. |
| What is the current EBITDA of Nanobiotix? | Nanobiotix's last 12-month EBITDA is -$63.0M. |
| What is the current EV/Revenue multiple of Nanobiotix? | Current revenue multiple of Nanobiotix is -418.3x. |
| What is the current EV/EBITDA multiple of Nanobiotix? | Current EBITDA multiple of Nanobiotix is -2.4x. |
| What is the current revenue growth of Nanobiotix? | Nanobiotix revenue growth between 2023 and 2024 was -139%. |
| Is Nanobiotix profitable? | Yes, Nanobiotix is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
